Anebulo Pharmaceuticals (NASDAQ:ANEB) Releases Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) issued its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Trading Up 0.5 %

ANEB stock traded up $0.01 during trading hours on Friday, hitting $1.97. 3,260 shares of the stock traded hands, compared to its average volume of 6,842. The stock has a 50-day simple moving average of $2.05 and a 200 day simple moving average of $2.35. Anebulo Pharmaceuticals has a one year low of $1.62 and a one year high of $3.61. The company has a market cap of $51.09 million, a P/E ratio of -5.30 and a beta of -1.01.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.